ArticleFrontiers in nutrition2025
Validation of the hypothesis on the protective role of functional beverages in mitigating the adverse health effects of digital technologies.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The widespread adoption of digital technologies (DT) and artificial intelligence (AI) has led to the emergence of digital stress (DS), characterized by anxiety, cognitive overload, visual fatigue, and emotional exhaustion. This study aims to validate the objective that functional beverages (FB), containing vitamins, minerals, probiotics, adaptogens, and antioxidants, can mitigate the adverse health effects of DS. The outlook of this objective includes the following: (1) assessing the protective potential of FB in reducing stress, enhancing cognitive function, protecting vision, normalizing sleep, and preventing the hereditary transmission of stress; (2) developing recommendations for next-generation FB with a focus on synergistic formulations and personalized approaches; and (3) justifying the use of advanced delivery technologies to enhance component bioavailability. A systematic review of empirical data confirmed the protective role of FB, demonstrating their effectiveness in alleviating DS consequences. Strategies for FB development were proposed, including the use of nanoemulsions, liposomes, and AI models for personalization, ensuring scalability and practical implementation of the hypothesis. PROSPERO registration: CRD420251077775.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.